导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.11% | 3071/4773 |
| 近一周 | -2.63% | 2726/5462 |
| 近一月 | -6.87% | 3659/5421 |
| 近一季 | -11.95% | 3788/5209 |
| 近半年 | -5.19% | 2774/4920 |
| 近一年 | -3.59% | 3063/4366 |
| 近两年 | 37.27% | 2003/2954 |
| 近三年 | 13.88% | 1662/2253 |
| 成立以来 | 121.80% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.40% 2779/4961 |
17.10% 1495/5312 |
- - |
- - |
| 2025 | 16.38% 2458/4813 |
-1.32% 2634/3635 |
-0.75% 3017/4076 |
23.87% 1508/4524 |
-4.07% 3387/4813 |
| 2024 | 8.19% 1579/3463 |
0.45% 975/2808 |
-3.19% 1317/3014 |
14.74% 1916/3129 |
-3.03% 2237/3463 |
| 2023 | -12.33% 1470/2656 |
5.54% 774/2280 |
-5.70% 1520/2385 |
-5.88% 1389/2515 |
-6.42% 1763/2655 |
| 2022 | -22.69% 1080/2207 |
-17.68% 1240/1919 |
8.94% 315/2016 |
-14.47% 1100/2113 |
0.79% 1451/2208 |
| 2021 | -3.21% 895/1822 |
-4.44% 864/1255 |
6.48% 743/1330 |
-7.35% 1046/1466 |
2.66% 541/1822 |
| 2020 | 47.71% 194/1250 |
-4.57% 375/1028 |
20.61% 266/1067 |
11.24% 463/1164 |
15.36% 213/1184 |
| 2019 | 39.14% 289/1092 |
27.49% 345/754 |
-1.60% 319/804 |
3.54% 247/850 |
7.12% 483/918 |
| 2018 | -27.12% 415/834 |
- - |
- - |
- - |
-13.59% 543/691 |
| 2017 | 19.86% 190/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.67% 180/605 |
- - |
- - |
- - |
- - |
| 2015 | 18.14% 129/575 |
- - |
- - |
- - |
- - |
| 2014 | 24.74% 184/237 |
- - |
- - |
- - |
- - |
| 2013 | 4.05% 58/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |